GILD · News · 20260922N
HIV Prevention Access Expansion
GILEAD SCIENCES, INC. · 2026-09-22 · Importance 31 · Surprise 42 · In source text
Gilead is extending royalty-free licenses for the HIV prevention medicine lenacapavir. The company also signed a new access agreement with the Pan American Health Organization. The reported actions expand access to lenacapavir across participating markets, but the digest did not disclose deal value or expected revenue impact.
Key facts
- Gilead Sciences is expanding its HIV prevention efforts by extending royalty-free licenses for lenacapavir. source
- Gilead Sciences signed a new access agreement with the Pan American Health Organization. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | committed | — | Gilead Sciences is expanding its HIV prevention efforts by extending royalty-free licenses for lenacapavir. |
| revenue | unclear | committed | — | Gilead Sciences signed a new access agreement with the Pan American Health Organization. |